On September 26, 2023, Avalo Therapeutics, Inc. closed the transaction. The company received $5 million in its third and final tranche. The transaction bringing total funding to $35 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.1 USD | +15.75% | +2.59% | +21.98% |
13/05 | Avalo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
17/04 | North American Morning Briefing : Stock Futures -2- | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+21.98% | 11.48M | |
+41.79% | 54.04B | |
+46.23% | 41.96B | |
-0.56% | 41.92B | |
-7.20% | 28.35B | |
+12.59% | 26.35B | |
-21.51% | 19B | |
+6.92% | 13B | |
+29.60% | 12.28B | |
+24.91% | 12.19B |
- Stock Market
- Equities
- AVTX Stock
- News Avalo Therapeutics, Inc.
- Avalo Therapeutics, Inc. announced that it has received $35 million in funding from Horizon Technology Finance Management, LLC